

Nancy J Devlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3143066/publications.pdf>

Version: 2024-02-01

114
papers

8,429
citations

101384

36
h-index

49773

87
g-index

119
all docs

119
docs citations

119
times ranked

10841
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review. <i>Quality of Life Research</i> , 2022, 31, 79-89.	1.5	9
2	How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents. <i>Pharmacoeconomics</i> , 2022, 40, 157-182.	1.7	8
3	A Comparison of PROPr and EQ-5D-5L Value Sets. <i>Pharmacoeconomics</i> , 2022, 40, 297-307.	1.7	14
4	The relationship between physical and mental health multimorbidity and children's health-related quality of life. <i>Quality of Life Research</i> , 2022, 31, 2119-2131.	1.5	11
5	Longitudinal study of patients' health-related quality of life using EQ-5D-3L in 11 Swedish National Quality Registers. <i>BMJ Open</i> , 2022, 12, e048176.	0.8	8
6	Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures. <i>Pharmacoeconomics</i> , 2022, 40, 379-431.	1.7	28
7	An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. <i>Value in Health</i> , 2022, , .	0.1	2
8	The Development of the EQ-5D-5L and its Value Sets. , 2022, , 1-12.		8
9	Guidance to Users of EQ-5D-5L Value Sets. , 2022, , 213-233.		3
10	Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. <i>Vaccine</i> , 2022, 40, 4008-4016.	1.7	12
11	Preference Elicitation Techniques Used in Valuing Children's Health-Related Quality-of-Life: A Systematic Review. <i>Pharmacoeconomics</i> , 2022, 40, 663-698.	1.7	5
12	Valuing Child Health Isn't Child's Play. <i>Value in Health</i> , 2022, 25, 1087-1089.	0.1	8
13	Giving a Voice to Marginalised Groups for Health Care Decision Making. <i>Patient</i> , 2021, 14, 5-10.	1.1	6
14	Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?. <i>Medical Decision Making</i> , 2021, 41, 584-596.	1.2	30
15	Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1950-1977.	0.8	8
16	EQ-5D-5L Health-State Values for the Mexican Population. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 905-914.	1.0	11
17	Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 635-644.	1.0	8
18	Psychometric Performance of HRQoL Measures: An Australian Paediatric Multi-Instrument Comparison Study Protocol (P-MIC). <i>Children</i> , 2021, 8, 714.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Variations in Patientsâ€™ Overall Assessment of Their Health Across and Within Disease Groups Using the EQ-5D Questionnaire: Protocol for a Longitudinal Study in the Swedish National Quality Registers. JMIR Research Protocols, 2021, 10, e27669.	0.5	4
20	Sugammadex, neostigmine and postoperative pulmonary complications: an international randomised feasibility and pilot trial. Pilot and Feasibility Studies, 2021, 7, 200.	0.5	8
21	International guidelines for self-report and proxy completion of paediatric health-related quality of life measures: a protocol for a systematic review. BMJ Open, 2021, 11, e052049.	0.8	2
22	Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?. Pharmacoeconomics, 2020, 38, 325-340.	1.7	86
23	A new tool for creating personal and social EQ-5D-5L value sets, including valuing â€œdeadâ€™. Social Science and Medicine, 2020, 246, 112707.	1.8	31
24	Methods for Analysing and Reporting EQ-5D Data. , 2020, , .		125
25	The EQ-5D-5L Value Set for England: Response to the â€œQuality Assuranceâ€™. Value in Health, 2020, 23, 649-655.	0.1	16
26	An exploration of methods for obtaining 0â€™=â€™dead anchors for latent scale EQ-5D-Y values. European Journal of Health Economics, 2020, 21, 1091-1103.	1.4	36
27	Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5â€™L valuation study in Ireland. Health Policy, 2020, 124, 639-646.	1.4	4
28	International Valuation Protocol for the EQ-5D-Y-3L. Pharmacoeconomics, 2020, 38, 653-663.	1.7	84
29	An Introduction to EQ-5D Instruments and Their Applications. , 2020, , 1-22.		16
30	Analysis of EQ-5D Profiles. , 2020, , 23-49.		13
31	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. Journal of Patient-Reported Outcomes, 2020, 4, 22.	0.9	6
32	Analysis of EQ VAS Data. , 2020, , 51-59.		1
33	Analysis of EQ-5D Values. , 2020, , 61-86.		9
34	Health today versus health tomorrow: does Australia really care less about its future health than other countries do?. Australian Health Review, 2020, 44, 337.	0.5	5
35	A new method for valuing health: directly eliciting personal utility functions. European Journal of Health Economics, 2019, 20, 257-270.	1.4	26
36	Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. European Journal of Health Economics, 2019, 20, 99-105.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?. Value in Health, 2019, 22, 45-49.	0.1	31
38	Cultural Values: Can They Explain Differences in Health Utilities between Countries?. Medical Decision Making, 2019, 39, 605-616.	1.2	42
39	All Male Panels and Other Diversity Considerations for ISPOR. PharmacoEconomics - Open, 2019, 3, 423-426.	0.9	0
40	A note on the relationship between age and health-related quality of life assessment. Quality of Life Research, 2019, 28, 1201-1205.	1.5	6
41	Distribution of the EQ-5D-5L Profiles and Values in Three Patient Groups. Value in Health, 2019, 22, 355-361.	0.1	10
42	Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management. Journal of Wound Care, 2018, 27, 156-165.	0.5	8
43	3L, 5L, What the L? A NICE Conundrum. PharmacoEconomics, 2018, 36, 637-640.	1.7	28
44	Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. PharmacoEconomics, 2018, 36, 699-713.	1.7	74
45	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). PharmacoEconomics - Open, 2018, 2, 153-163.	0.9	22
46	New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics (United Kingdom), 2018, 27, 23-38.	0.8	61
47	Valuing EQ-5D-5L health states "in context" using a discrete choice experiment. European Journal of Health Economics, 2018, 19, 595-605.	1.4	8
48	Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics (United Kingdom), 2018, 27, 23-38.	0.8	863
49	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. Value in Health, 2018, 21, 1291-1298.	0.1	70
50	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncology, The, 2018, 19, e459-e469.	5.1	66
51	Euthanasia, religiosity and the valuation of health states: results from an Irish EQ5D5L valuation study and their implications for anchor values. Health and Quality of Life Outcomes, 2018, 16, 152.	1.0	8
52	Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. PharmacoEconomics, 2018, 36, 1345-1353.	1.7	67
53	A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?. Applied Health Economics and Health Policy, 2017, 15, 469-477.	1.0	16
54	EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 2017, 15, 127-137.	1.0	684

#	ARTICLE	IF	CITATIONS
55	Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>Quality of Life Research</i> , 2017, 26, 1187-1195.	1.5	5
56	An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. <i>Quality of Life Research</i> , 2017, 26, 2067-2078.	1.5	27
57	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. <i>European Journal of Health Economics</i> , 2017, 18, 967-977.	1.4	8
58	Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. <i>Patient</i> , 2017, 10, 677-686.	1.1	8
59	Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 130.	1.0	27
60	QALYs as a measure of value in cancer. <i>Journal of Cancer Policy</i> , 2017, 11, 19-25.	0.6	38
61	The effect of religion on the perception of health states among adults in the United Arab Emirates: a qualitative study. <i>BMJ Open</i> , 2017, 7, e016969.	0.8	19
62	What Determines the Shape of an EQ-5D Index Distribution?. <i>Medical Decision Making</i> , 2016, 36, 941-951.	1.2	33
63	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. <i>Lancet Oncology</i> , The, 2016, 17, e510-e514.	5.1	158
64	Opportunity costs and local health service spending decisions: a qualitative study from Wales. <i>BMC Health Services Research</i> , 2016, 16, 103.	0.9	19
65	Multiple Criteria Decision Analysis for Health Care Decision Making – An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 1-13.	0.1	437
66	Assessing Patient-Reported Outcomes in Pediatric Populations With Vaccine-Preventable Infectious Diseases: A Systematic Review of the Literature (the PROCHID Study). <i>Value in Health</i> , 2016, 19, 109-119.	0.1	3
67	Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. <i>Value in Health</i> , 2016, 19, 255-266.	0.1	19
68	Multiple Criteria Decision Analysis for Health Care Decision Making – Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 125-137.	0.1	320
69	UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 363-370.	0.2	6
70	INTER – PROVIDER COMPARISON OF PATIENT – REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX. <i>Health Economics (United Kingdom)</i> , 2015, 24, 41-54.	0.8	22
71	The Influence of Cost – Effectiveness and Other Factors on Nice Decisions. <i>Health Economics (United Kingdom)</i> 10.784314	0.8	186
72	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates. <i>Value in Health Regional Issues</i> , 2015, 7, 34-41.	0.5	20

#	ARTICLE	IF	CITATIONS
73	Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 171.	1.0	124
74	Association between market concentration of hospitals and patient health gain following hip replacement surgery. <i>Journal of Health Services Research and Policy</i> , 2015, 20, 11-17.	0.8	19
75	Putting patient-reported outcomes on the "Big Data Road Map". <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 299-303.	1.1	34
76	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). <i>Pharmacoeconomics</i> , 2015, 33, 867-877.	1.7	45
77	Local health care expenditure plans and their opportunity costs. <i>Health Policy</i> , 2015, 119, 1237-1244.	1.4	16
78	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. <i>Health Technology Assessment</i> , 2015, 19, 1-504.	1.3	536
79	What Determines the Shape of an EQ-5D Index Distribution?. <i>SSRN Electronic Journal</i> , 2014, , .	0.4	2
80	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. <i>Medical Care</i> , 2014, 52, 935-943.	1.1	38
81	A Study of the Relationship between Health and Subjective Well-Being in Parkinson's Disease Patients. <i>Value in Health</i> , 2014, 17, 372-379.	0.1	27
82	A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol. <i>Value in Health</i> , 2014, 17, 445-453.	0.1	341
83	Assessing the performance of the EQ-VAS in the NHS PROMs programme. <i>Quality of Life Research</i> , 2014, 23, 977-989.	1.5	192
84	Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data. <i>Health Services and Delivery Research</i> , 2014, 2, 1-90.	1.4	20
85	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. <i>Health Technology Assessment</i> , 2014, 18, vii-xxvi, 1-191.	1.3	47
86	A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO. <i>Health Economics (United Kingdom)</i> , 2013, 33, 100-111.	0.8	51
87	The development of new research methods for the valuation of EQ-5D-5L. <i>European Journal of Health Economics</i> , 2013, 14, 1-3.	1.4	205
88	The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. <i>European Journal of Health Economics</i> , 2013, 14, 15-24.	1.4	24
89	Lead versus lag-time trade-off variants: does it make any difference?. <i>European Journal of Health Economics</i> , 2013, 14, 25-31.	1.4	33
90	Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. <i>European Journal of Health Economics</i> , 2013, 14, 43-51.	1.4	25

#	ARTICLE	IF	CITATIONS
91	One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. <i>European Journal of Health Economics</i> , 2013, 14, 65-73.	1.4	23
92	Operationalizing Value-Based Pricing of Medicines. <i>Pharmacoeconomics</i> , 2013, 31, 1-10.	1.7	84
93	Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions. <i>Medical Decision Making</i> , 2013, 33, 804-818.	1.2	39
94	The Influence of Cost-Effectiveness and Other Factors on NICE Decisions. <i>SSRN Electronic Journal</i> , 2013, , .	0.4	9
95	Comparison of the Underlying Constructs of the EQ-5D and Oxford Hip Score: Implications for Mapping. <i>Value in Health</i> , 2011, 14, 884-891.	0.1	26
96	A uniform time trade off method for states better and worse than dead: feasibility study of the "lead time" approach. <i>Health Economics (United Kingdom)</i> , 2011, 20, 348-361.	0.8	111
97	Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. <i>Quality of Life Research</i> , 2010, 19, 875-886.	1.5	574
98	Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. <i>Quality of Life Research</i> , 2010, 19, 887-897.	1.5	325
99	Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. <i>Health Economics (United Kingdom)</i> , 2010, 19, 886-905.	0.8	206
100	Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review. <i>Medical Decision Making</i> , 2010, 30, 610-619.	1.2	56
101	Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?. <i>Medical Decision Making</i> , 2010, 30, 556-565.	1.2	76
102	The Economics of a "Liberated" NHS. <i>Pharmacoeconomics</i> , 2010, 28, 1075-1078.	1.7	3
103	An Analysis of NICE's "Restricted" (or "Optimized") Decisions. <i>Pharmacoeconomics</i> , 2010, 28, 987-993.		21
104	"Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. <i>Health Policy</i> , 2006, 77, 352-367.	1.4	112
105	Is there a case for using visual analogue scale valuations in cost-utility analysis?. <i>Health Economics (United Kingdom)</i> , 2006, 15, 653-664.	0.8	155
106	Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. <i>Health Economics (United Kingdom)</i> , 2004, 13, 437-452.	0.8	609
107	Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. <i>Health Economics (United Kingdom)</i> , 2003, 12, 529-544.	0.8	81
108	PRIORITIZING PATIENTS FOR ELECTIVE SURGERY. <i>International Journal of Technology Assessment in Health Care</i> , 2003, 19, 91-105.	0.2	47

#	ARTICLE	IF	CITATIONS
109	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates. SSRN Electronic Journal, 0, , .	0.4	1
110	Assessing the Performance of the EQ-VAS in the NHS PROMs Programme. SSRN Electronic Journal, 0, , .	0.4	3
111	Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches. SSRN Electronic Journal, 0, , .	0.4	2
112	A Comparison of Alternative Variants of the Lead and Lag Time TTO. SSRN Electronic Journal, 0, , .	0.4	2
113	Time to Tweak the TTO: But How?. SSRN Electronic Journal, 0, , .	0.4	0
114	The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states. Wellcome Open Research, 0, 7, 14.	0.9	7